An aqueous immunogenic composition which, after administration to a subject, is able to induce an immune response that is (a) bactericidal against at least serogroup W135 of N.meningitidis and (b) protective against H influenzae type b disease, wherein the composition comprises: (i) a conjugated serogroup W135 capsular saccharide antigen and (ii) a conjugated H influenzae type b (Hib) capsular saccharide antigen. The conjugated serogroup W135 saccharide may be conjugated, for example, to a diphtheria toxoid, a tetanus toxoid, a H.influenzae protein D, a tetanus toxoid, and may include an aluminium phosphate adjuvant. The conjugated serogroup W135 saccharide may be conjugated to a CRM197 diphtheria toxin mutant, the composition comprising < 30 µg meningococcal saccharide per dose.
